Serum haptoglobin and alpha 1-acid glycoprotein as indicators of the effectiveness of cis-diamminedichloroplatinum (CDDP) in ovarian cancer patients--a preliminary report.
Twenty-one patients with adenocarcinoma of the ovary were given a maximum of five courses of CDDP by i.v. infusion every 4 weeks. With one exception, the serum levels of both haptoglobin and alpha 1-acid glycoprotein correlate with tumour burden before therapy and at follow-up. It is suggested that a more accurate assessment of the effectiveness of CDDP therapy may be obtained by estimating these serum proteins before each infusion than by an abdominal examination.